SEMAX

Cognitive EnhancementResearch Only

Solid research foundation with genuine human clinical data, though most studies come from Russian institutions. The evidence for cognitive benefits and neuroprotection is more robust than typical nootropics.

Predominantly studied by Russian and Eastern European neurologists treating stroke recovery, cognitive decline, and attention disorders.

FDA Status

Banned from Compounding

Since Mar 2024

Evidence

Strong

Studies

30 total, 13 human

What is SEMAX?

Originally developed by Soviet researchers as a derivative of the stress hormone ACTH, this seven-amino acid peptide has become one of the most studied nootropics in Eastern European research. Unlike many cognitive enhancers, Semax operates without affecting cortisol or other stress hormones, making it an unusual member of the ACTH family. Russian medical institutions have used it clinically for decades to treat stroke patients and cognitive decline.

Rather than mimicking ACTH's hormonal effects, Semax appears to boost production of brain-derived neurotrophic factor (BDNF), a protein that promotes new brain cell growth and protects existing neurons from damage. The peptide also influences dopamine and serotonin pathways in ways that researchers believe improve information processing and memory formation. Think of it as providing the brain with better building materials and maintenance tools without triggering a stress response.

What the Research Shows

While 13 human studies provide meaningful clinical data, the research landscape is geographically concentrated, with most trials conducted in Russia using relatively small sample sizes.

Clinical evidence for SEMAX comprises 20 human studies including 3 randomized controlled trials, with key findings demonstrating effects on neurogenesis and progenitor cell proliferation, modulation of blood coagulation with anticoagulant potential, and reduction of ischemic damage in animal models, though functional neuroimaging studies show distinct connectivity changes in amygdala and prefrontal regions compared to the related peptide Selank.